

Ambee Pharmaceuticals Limited
Audited Financial Statement
As on 30 June 2023

**Independent Auditor's Report
To the Shareholders of Ambee Pharmaceuticals PLC**

Report on the Audit of the Financial Statements

Qualified and Disclaimer of Opinion

We have audited the Financial Statements of Ambee Pharmaceuticals PLC, which comprise the Statement of Financial Position as at June 30, 2023 and the Statement of Profit or Loss and Other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year then ended, and Notes to the Financial Statements, including a summary of significant accounting policies.

In our opinion, except for the effects of the matter described in the Basis for Qualified Opinion and Basis for Disclaimer of opinion section of our report, the accompanying Financial Statements present fairly, in all material respects, the financial position of the Company as at June 30, 2023 and its financial performance and its cash flows for the year then ended in accordance with International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs).

Basis for Qualified Opinion

1. As disclosed in note no 17.01 the company reported an amount of Tk. 431,369 as Income Tax Deduction from Suppliers. The amount is carry forward from earlier years. The company has not deposited the entire amount of TDS to the Government Treasury within the stipulated time. As per Income Tax Act, 2023 sec 143 (3) any person who fails to deposit such TDS to the Government Treasury, the responsible party shall be liable to pay an additional amount at the rate of 2% per month.
2. As disclosed in note # 17.01, the company has shown Tk. 1,916,358 as Payable to Provident Fund. The amount is carried forward from earlier years. As disclosed in note # 3.07 (a) the provided fund is a recognized fund but no Financial Statement of Provident Fund was made available to us, so we are not sure whether there is any forfeited fund returned to company's account from the contributory provident fund as per notification no. 179/FRC/FRM/2020/2, dated July 07, 2020 of the Financial Reporting Council (FRC).
3. As disclosed in note # 17.02 to the Financial Statements an amount of Tk.13,441,194 has been shown as VAT Payable as at 30.06.2023. The company has not deposited the entire amount of VAT deducted at source to the Government Treasury within the stipulated time. As per Section 127 of Value Added Tax and Supplementary Duty Act, 2012 any person who fails to pay the VAT on or before the due date, shall be liable to pay simple interest @ 1% monthly on the amount of VAT payable from the day following the due date to the date of payment.
4. As disclosed in note # 19.00, the company has shown Tk. 11,713,039 as liabilities for WPWF which includes prior year's amount of Tk. 10,459,676. During the year an amount of Tk. 511,723 has been paid by the company. As per section 234 (b) of Labour Act, 2006 the company should pay the full amount to the WPWF not later than nine months from the end of the respective year. Incase of failure penalty as per section 236 may be imposed. However, for utilization of the fund the company provided interest as per section 240
5. As disclosed in note # 20.00, the company has shown an amount of Tk. 1,758,129 as Unclaimed Dividend as at 30.06.2023. The designated bank account for dividend has shown a balance of Tk. 370,819 as at 30.06.2023. Hence, there is a shortfall in the dividend bank account. This is a non-compliance of the section 28 (1) of Dhaka Stock Exchange (Listing) Regulations, 2015. However during the year company has paid lump Sum Tk. 1,000,000 to the Capital Market Stabilization Fund (CMSF) as per directive of Bangladesh Securities Exchange Commission (BSEC) No. SEC/SRMIC/165-2020/part-1/202 dated 25, August 2021.

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) together with the ethical requirements that are relevant to our audit of the Financial Statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these ethical requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion and Disclaimer of opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Financial Statements of the current period. These matters were addressed in the context of our audit of the Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Risk	How the matter was addressed in our audit
<p>Valuation of Property, Plant and Equipment (PPE)</p> <p>The carrying value of the PPE was Tk. 87,475,536 as at 30 June, 2023. Expenditures are capitalized if they create new assets or enhance the existing assets, and expensed if they relate to repair or maintenance of the assets. Classification of the expenditures involves judgment. The useful lives of PPE items are based on management's estimates regarding the period during which the assets or its significant components will be used. The estimates are based on historical experience and market practice and take into consideration the physical condition of the assets.</p> <p>The valuation of PPE was identified as a key audit matter due to the significance of this balance to the Financial Statements and that there is significant measurement uncertainty involved in this valuation.</p>	<p>Our audit included the following procedures: We assessed whether the accounting policies in relation to the capitalization of expenditures are in compliance with IFRS and found them to be consistent.</p> <p>We obtained a listing of capital expenditures incurred during the year and on a sample basis, checked whether the items were procured based on internal purchase order that had been properly approved by the responsible individuals.</p> <p>We inspected a sample of invoices and L/C documents to determine whether the classification between capital and revenue expenditure was appropriate.</p> <p>We evaluated whether the useful lives determined and applied by the management were in line with historical experience and the market practice.</p> <p>We checked whether the depreciation of PPE items was commenced timely, by comparing the date of the reclassification from capital work in progress to ready for use, with the date of the act of completion of the work.</p>
<p>See Schedule-A to the Financial Statements</p>	

<p>Implementation of IFRS 16 Leases</p> <p>The Right of use (ROU) of Tk. 137,342 as at 30 June, 2023 IFRS 16 modifies the accounting treatment of operating leases at inception, with the recognition of a right of use (ROU) on the leased assets and of a liability for the lease payments over the lease contract term. With respect to operating leases of premises used by the Company, at inception of the lease, the lessee receives a right of using the premises, in exchange of a lease debt, using an implicit discount rate.</p> <p>All leasing arrangements within the scope of IFRS 16 are identified and appropriately included in the calculation of the transitional impact and specific</p>	<p>We reviewed appropriateness of management's application of IFRS 16 and assessment of the impact on the Financial Statements. Our audit procedures included testing classification and measurement of right-of-use assets and lease liabilities in accordance with IFRS 16. We checked the present value calculation for lease. We reviewed loan agreements and made calculation to ascertain the appropriateness of the incremental borrowing rate used. We also examined the accuracy and appropriateness of accounting adjustments in the Financial Statements arising from the adoption of IFRS 16 as well as verified the sufficiency and appropriateness of disclosures in the Financial Statements.</p>
--	--

assumptions applied to determine the discount rates for lease are appropriate.	
See Note 4.00 to the Financial Statements	

Valuation of Inventory	
<p>The inventory of Tk. 197,247,925 as at 30 June, 2023 held in factory, depots and outlets.</p> <p>Inventories are carried at the lower of cost and net realizable value.</p> <p>Since the value of Inventory is significant to the Financial Statements and there is significant measurement uncertainty involved in this valuation, the valuation of inventory was significant to our audit.</p>	<p>We verified the appropriateness of management's assumptions applied in calculating the value of the inventory by:</p> <ul style="list-style-type: none"> • Evaluating the design and implementation of key inventory controls operating across the factory, depots and outlets; • Evaluating, on a sample basis, whether • inventories were stated at the lower of cost or net realizable value at the reporting date by comparing the sales prices of inventories subsequent to the reporting date; and <p>Evaluating the adequacy of Financial Statement disclosure as per IAS – 2.</p>
See Note 5.00 to the Financial Statements	

Cash & Cash Equivalents	
<p>Cash & Cash Equivalents of TK 28,567,933 represent Cash in Hand and Cash with banks at the close of business of the company which can be used without any obligation.</p> <p>As those are liquid funds, as per practice it is important to confirm and verify the actual balances of cash & cash equivalents.</p>	<ul style="list-style-type: none"> • We could not physically verify the cash in hand as our appointment was communicated on July 15, 2021 i.e., after closing of the year. However, the cash balance is duly certified by the management. The company management has physically counted cash in hand at head office and factory only. • We requested the management to send letters to banks to confirm their balances as on June 30, 2021 directly to us but no such confirmation has yet been received.
See Note 09.00 to the Financial Statements	

Deferred Tax Liability	
<p>The Deferred Tax Liability balance was Tk. 6,123,425 as at June 30, 2023.</p> <p>Significant management judgment is required in relation to deferred tax Liability as it is dependent on forecasts of future profitability over a number of years.</p> <p>There is significant measurement uncertainty involved in this valuation and therefore it was significant to our audit.</p>	<p>We carried out the following substantive testing to address the related risk:</p> <ul style="list-style-type: none"> • We obtained an understanding, evaluated the design and tested the operational effectiveness of the Company's key controls over the recognition and measurement of deferred tax Liability assumptions used in estimating the Company's future taxable income. • We also assessed the completeness and accuracy of the data used for the estimations of future taxable income. • We assessed key assumptions, controls, recognition

	and measurement of Deferred Tax Liability. We also assessed the appropriateness of presentation of disclosure against IAS-12 Income Taxes.
See Note 12.00 to the Financial Statements	

Workers Participation and Welfare Fund (WPWF):	
Contribution to workers' profit participation fund: As per section 234(1)(b) of Bangladesh Labour Act, 2006 (as amended in 2013) 5% of the net profit, not later than nine (9) months from the close of that period, is required to be transferred to the Fund, the proportion of the payment to the Participation Fund and the Welfare Fund being 80:10. The remaining 10% of the amount of net profit shall be paid by the Company to the Workers' Welfare Foundation Fund, as formed under the provision of the Bangladesh Worker's Welfare Foundation Act, 2006. Of the 80% being transferred to the participation fund, two-third has to be distributed in equal proportions to all the members (beneficiary) of the fund in cash and one-third has to be invested in accordance with the manner as stated in section 242 of that Act.	We have checked the adequacy of WPWF fund provision and distribution thereof and observed that, the requirement of the Labour Act, 2006 (as amended in 2013) not followed properly. During the year, no distribution among the members and no payment of Government portion have been made. However, Interest on undistributed amount has been provided in the accounts.
See Note 19.00 to the Financial Statements	

Revenue Recognition	
At year end the Company reported total revenue of BDT 198,095,938 (2022: BDT 180,993,450) Revenue recognition has a significant and wide influence on the Financial Statements. Revenue is recognized when the amounts and the related costs are reliably measured, and the performance obligation is complete through passing of control to the customers. Revenue from the sale of goods is recognized at the time when the goods are dispatched for delivery to the customer. We identified revenue recognition as a key audit matter because revenue is one of the key performance indicators of the Company and therefore there is an inherent risk of manipulation of the timing of recognition of revenue by management to meet specific targets or expectations.	Our audit procedures in this area included, among others: <ul style="list-style-type: none"> • We understood, evaluated and validated the key controls related to the Company's sales process from end to end, from contracts approval and sign-off, recording of sales, all the way through to cash receipts and customers' outstanding balances. • Furthermore, we tested the sales transactions recognized shortly before and after the statement of financial position date, including the sales returns recorded after that date, to test whether sales transactions were recorded in the correct reporting periods. • Finally, we assessed the appropriateness and presentation of disclosures against IFRS 15 Revenue from Contracts with Customers.
See Note 21.00 to the Financial Statements	

Transactions with Related Parties	
We considered the related party transactions to be significant to the audit due to the risk that if these transactions are not conducted at arm's length, and/or the accounting treatment of the rights and obligations of these transactions are not correct, it could influence the results of the Financial Statement. Furthermore, for financial reporting purposes,	Our audit procedures included, among others, the following: <ul style="list-style-type: none"> • We obtained an understanding of the process for identifying related party transactions; • We verified that the transactions are approved in accordance with internal procedures including involvement of key personnel at the appropriate

<p>IAS 24 related party disclosure, requires complete and appropriate disclosure of transactions with related parties.</p>	<p>level;</p> <ul style="list-style-type: none"> • We checked the acquisitions to supporting documents including external valuations around the acquisition date to evaluate the managements' assertions that the transactions were at arm's length; • We evaluated the business rationale of the transactions; • We evaluated the rights and obligations per the terms and conditions of the agreements and assessed whether the transactions were recorded appropriately; and <p>We determined whether the directors have disclosed relationships and transactions in accordance with IAS 24.</p>
<p>See Note 30.00 to the Financial Statements</p>	

Other Information

Management as well as Directors are responsible for the other information. The other information comprises all of the information in the Annual Report other than the Financial Statements and our auditors' report thereon. The Annual Report is expected to be made available to us after the date of this auditor's report.

Our opinion on the Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the Financial Statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on such work we perform, we conclude that there is a material misstatement of this other information; we are required to communicate the matter to those charged with governance.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management as well as Directors are responsible for the preparation and fair presentation of the Financial Statements in accordance with IFRSs, and for such internal control as management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error. In preparing the Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Financial Statements are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery,

intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Company' Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act, 1994 and the Securities and Exchange Rules, 2020, we also report the following:

- a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) In our opinion, proper books of accounts as required by law have been kept by the Ambee Pharmaceuticals PLC so far as it appeared from our examination of these books;
- c) The Statements of Financial Position as at June 30, 2023 and Statements of Profit or Loss and Other Comprehensive Income dealt with by the report are in agreement with the books of accounts; and
- d) The expenditure incurred was for the purposes of the Company's business.

FOR A. WAHAB & CO.
CHARTERED ACCOUNTANTS



Md. Showkat Hossain, FCA
Partner

Enrolment No.-196
DVC:2311090196AS406737

Dated: Dhaka, November 05, 2023

Ambee Pharmaceuticals PLC
Statement of Financial Position
As at June 30, 2023

Particulars	Notes	30-06-2023	30-06-2022
<u>ASSETS</u>			
Non-Current Assets		87,612,878	95,042,142
Property, Plant & Equipment	Schedule-A	87,475,536	94,355,614
Right-of-Use Asset (ROU)	4.00	137,342	686,528
Current Assets		426,437,829	409,105,276
Inventories	5.00	197,247,925	178,888,046
Accounts Receivable	6.00	135,943,955	112,510,672
Advance Income Tax	7.00	19,578,293	49,296,762
Advances, Deposits and Pre-payments	8.00	45,099,723	51,486,460
Cash & Cash Equivalents	9.00	28,567,933	16,923,336
Total Assets		514,050,707	504,147,418
<u>EQUITY & LIABILITIES</u>			
Shareholders' Equity		23,341,189	52,695,498
Share Capital	10.00	24,000,000	24,000,000
Tax-Holiday Reserve	11.00	5,134,154	5,134,154
Retained Earnings		(5,792,965)	23,561,344
Total Liabilities		490,709,518	451,451,920
Non-Current Liabilities		6,123,425	7,177,026
Deferred Tax Liability	12.00	6,123,425	7,167,130
Lease Finance (Non-Current Portion)	13.00	-	9,896
Current Liabilities and Provision		484,586,094	444,274,894
Lease Finance (Current Portion)	13.00	126,399	1,072,010
Short Term Borrowings	14.00	11,480,430	64,021,763
Creditors for Goods & Others	15.00	4,981,983	6,549,924
Liabilities for Expenses	16.00	6,025,487	7,201,295
Liabilities for Other Finance	17.00	417,362,190	316,269,940
Provision for Income Tax	18.00	31,540,212	36,343,933
Workers Participation and Welfare Fund	19.00	11,713,039	10,459,676
Unclaimed Dividend	20.00	1,356,352	2,356,352
Total Equity and Liabilities		514,050,707	504,147,418
Net Asset Value (NAV) Per Share	27.00	9.73	21.96


The annexed notes 01 to 39 form an integral part of these financial statements.



Naureen Aziz Mohammad Bhai
Vice Chairperson and Chief Executive Officer
(CEO)



Kazi Tanzina Ferdous
Managing Director



Nurjahan Huda
Director



A.K.M Khairul Aziz
Chief Financial Officer



Mohammad Amir Hossain
Company Secretary

Subject to our separate report of even date.




(A. WAHAB & CO.)
Chartered Accountants
Signed By: Md. Showkat Hossain, FCA
Enrolment No.-196
DVC:2311090196AS406737

Dated: Dhaka, November 06, 2023


AMBEE PHARMACEUTICALS PLC
Statement of Profit or Loss and Other Comprehensive Income
For the year ended June 30, 2023

Particulars	Notes	30-06-2023	30-06-2022
Revenue (Net)	21.00	198,095,938	180,993,450
Cost of Goods Sold	22.00	(94,967,192)	(88,742,122)
Gross Profit		103,128,746	92,251,328
Operating Expenses		(88,191,885)	(75,738,866)
Administrative Expenses	23.00	(23,005,820)	(20,323,652)
Selling, Distribution & Marketing Expenses	24.00	(65,186,065)	(55,415,214)
Profit from Operations		14,936,861	16,512,462
Financial Expenses	25.00	(3,692,399)	(5,766,289)
Profit before contribution to WPWF		11,244,462	10,746,173
Contribution to WPWF	19.00	(562,223)	(511,723)
Profit Before Tax		10,682,239	10,234,451
Income Tax Expenses		(1,592,093)	(2,175,201)
Income Tax Expenses-Current Year	18.00	(2,635,798)	(2,046,890)
Deferred Tax (Expenses)/Income	12.00	1,043,705	(128,311)
Net Profit After Tax		9,090,147	8,059,249
Earnings Per Share (EPS) Basic	26.00	3.79	3.36


The annexed notes 01 to 39 form an integral part of these financial statements.



Naureen Aziz Mohammad Bhai
Vice Chairperson and Chief Executive
Officer (CEO)



Kazi Tanzina Ferdous
Managing Director



Nurjahan Huda
Director



A.K.M Khairul Aziz
Chief Financial Officer



Mohammad Amir Hossain
Company Secretary

Subject to our separate report of even date.



(A. WAHAB & CO.)
Chartered Accountants
Signed By: Md. Showkat Hossain, FCA
Enrollment No.-196
DVC:2311090196AS406737

Dated: Dhaka, November 06, 2023

AMBEE PHARMACEUTICALS PLC
Statement of Changes in Equity
For the year ended June 30, 2023

A. WAHAB & CO.
Chartered Accountants

Particulars	Share Capital	Tax Holiday Reserve	Retained Earnings	Total
Balance as on 01 July 2022	24,000,000	5,134,154	23,561,344	52,695,498
Prior year adjustment-Provision for Tax (After completion of Assessment)	-	-	(5,392,629)	(5,392,629)
Prior year adjustment-Advance Income Tax (After completion of Assessment)	-	-	(30,651,827)	(30,651,827)
Cash Dividend for the year 2021-2022	-	-	(2,400,000)	(2,400,000)
Net Profit for the year after Tax	-	-	9,090,147	9,090,147
Balance as on 30 June 2023	24,000,000	5,134,154	(5,792,965)	23,341,190

For the year ended June 30, 2022

Particulars	Share Capital	Tax Holiday Reserve	Retained Earnings	Total
Balance as on 01 July 2021	24,000,000	5,134,154	15,702,953	44,837,107
Prior year adjustment-provision for Tax Assessment	-	-	(214,358)	(214,358)
Prior year adjustment-refund warrant payable and share application money	-	-	13,500	13,500
Net Profit for the year after Tax	-	-	8,059,249	8,059,249
Balance as on 30 June 2022	24,000,000	5,134,154	23,561,344	52,695,498


The annexed notes 01 to 39 form an integral part of these financial statements.



Naureen Aziz Mohammad Bhai
Vice Chairperson and Chief Executive Officer (CEO)



Kazi Tanzina Ferdous
Managing Director



Nurjahan Huda
Director



A.K.M Khairul Aziz
Chief Financial Officer



Mohammad Amir Hossain
Company Secretary

Subject to our separate report of even date.



(A. WAHAB & CO.)
 Chartered Accountants
 Signed By: Md. Showkat Hossain, FCA
 Enrolment No.-196
 DVC:2311090196AS406737

Dated: Dhaka, November 06, 2023


AMBEE PHARMACEUTICALS PLC
Statement of Cash Flows
For the year ended June 30, 2023

Particulars	Notes	30-06-2023	30-06-2022
A) Cash Flows From Operating Activities:			
Cash Receipts from Customers & Others	6.01	174,662,655	160,710,718
Payments for Costs, Expenses & Others		(190,734,651)	(222,276,365)
Cash Generated from Operating Activities		(16,071,996)	(61,565,647)
Finance Expenses			
Income Tax Paid		(3,692,399)	(5,766,289)
		(15,467,946)	(5,848,350)
Net Cash Generated from Operating Activities	29.00	(35,232,341)	(73,180,286)
B) Cash Flows From Investing Activities:			
Purchase of Property, Plant & Equipment		(106,750)	(1,530,490)
Net Cash (Used in)/Generated from Investing Activities		(106,750)	(1,530,490)
C) Cash Flows from Financing Activities:			
Other Finance			
Short Term Borrowings		101,480,527	132,688,797
Lease Finance		(52,541,333)	(51,558,755)
Dividend Paid		(955,507)	(3,089,780)
		(1,000,000)	(1,500,000)
Net Cash Used in Financing Activities		46,983,687	76,540,262
D) Net Change in Cash and Cash Equivalents (A+B+C)		11,644,597	1,829,486
E) Opening Cash and Cash Equivalents		16,923,336	15,093,850
F) Closing Cash and Cash Equivalents (D+E)	10.00	28,567,933	16,923,336
Net Operating Cash Flow Per Share	28.00	(14.68)	(30.49)

The annexed notes 01 to 39 form an integral part of these financial statements.



Naureen Aziz Mohammad Bhai
Vice Chairperson and Chief Executive
Officer (CEO)



Kazi Tanzina Ferdous
Managing Director



Nurjahan Huda
Director



A.K.M Khairul Aziz
Chief Financial Officer



Mohammad Amir Hossain
Company Secretary

Subject to our separate report of even date.



(A. WAHAB & CO.)
Chartered Accountants
Signed By: Md. Showkat Hossain, FCA
Enrolment No.-196
DVC:2311090196AS406737

Dated: Dhaka, November 06, 2023

AMBEE PHARMACEUTICALS PLC
Schedule of Property, Plant & Equipment
For the year ended June 30, 2023

Schedule-A

Particulars	Cost				Depreciation					Written Down Value as on 30.06.2023
	Balance as on 01.07.2022	Addition During the Year	Adjustment the during year	Balance as on 30.06.2023	Rate %	Balance as on 01.07.2022	Adjustment during the year	Charged During the Year	Balance as on 30.06.2023	
Existing Units -1										
Land	49,033,738	-	-	49,033,738	-	-	-	-	-	49,033,738
Leasehold Land	1,215,803	-	-	1,215,803	-	-	-	-	-	1,215,803
Factory Building	26,326,964	-	-	26,326,964	10	14,803,301	-	1,152,366	15,955,667	10,371,297
Plant and Machinery	62,248,702	-	-	62,248,702	20	49,460,240	-	2,557,692	52,017,932	10,230,770
Deep Tube Well	1,368,000	-	-	1,368,000	10	1,204,683	-	16,332	1,221,015	146,985
Diesel Generating Set	446,500	-	-	446,500	15	386,263	-	9,035	395,299	51,201
Loose Tools	98,001	-	-	98,001	10	95,654	-	235	95,889	2,112
Laboratory Equipment	3,608,756	-	-	3,608,756	10	2,541,542	-	106,721	2,648,263	960,493
Electrical Installation	556,455	-	-	556,455	10	315,775	-	24,068	339,843	216,612
Laboratory Glassware	41,626	-	-	41,626	10	41,540	-	9	41,549	77
Production Equipment	1,220,541	-	-	1,220,541	10	917,294	-	30,325	947,619	272,922
Transport and Vehicles	12,530,135	-	-	12,530,135	20	10,808,856	-	344,256	11,153,112	1,377,023
Motor Cycle	38,662,774	-	-	38,662,774	20	29,545,253	-	1,823,504	31,368,758	7,294,017
Furniture and Fixtures	3,510,681	-	-	3,510,681	10	2,846,717	-	66,396	2,913,114	597,567
Office Equipment	12,784,236	106,750	-	12,890,986	10	10,701,582	-	215,078	10,916,660	1,974,326
Office By-cycles	15,962	-	-	15,962	20	15,813	-	30	15,843	119
Books	98,060	-	-	98,060	10	93,072	-	499	93,571	4,489
Sub Total	213,766,933	106,750	-	213,873,683		123,777,586	-	6,346,547	130,124,135	83,749,549
Injectable (Ampoule) Unit -2										
Factory Building	3,627,409	-	-	3,627,409	10	1,422,465	-	220,494	1,642,959	1,984,450
Plant and Machinery	9,221,953	-	-	9,221,953	20	7,210,478	-	402,295	7,612,773	1,609,179
Production Equipment	80,500	-	-	80,500	10	68,829	-	1,167	69,996	10,504
Transport and Vehicles	2,235,000	-	-	2,235,000	20	2,209,929	-	5,014	2,214,943	20,057
Furniture and Fixture	930,903	-	-	930,903	10	817,795	-	11,311	829,106	101,797
Sub Total	16,095,764	-	-	16,095,764		11,729,496	-	640,281	12,369,777	3,725,987
June 30, 2023	229,862,697	106,750	-	229,969,447		135,507,083	-	6,986,828	142,493,911	87,475,536
June 30, 2022	228,332,207	1,530,490	-	229,862,697		130,721,879	-	4,785,208	135,507,083	94,355,614

Note : Depreciation Charged to :

(a) Cost of Goods Sold (Note - 22.00)	4,537,064
(b) Administrative Expenses (Note - 23.00)	2,449,764
	Tk. 6,986,828

30-06-2023

AMBEE PHARMACEUTICALS PLC
Notes to the Financial Statements
For the year ended June 30, 2023

1.00 Background and Introduction:

1.01 Incorporation and Legal Status

The Ambee Pharmaceuticals PLC was incorporated in Bangladesh as a public company on 4th February, 1976 vide Certificate of Incorporation No. C47.14/132 of 1975-1976. It commenced commercial operation in 1978 and went for public issue of shares in 1986. The shares of the Company are listed in the Dhaka and Chittagong Stock Exchanges of Bangladesh.

The registered office and the manufacturing plant of the company is located at 184/1, Tejgaon I/A, Dhaka-1208.

1.02 Nature of Business:

The nature of business of the company is to manufacture, buy, sell, export, or otherwise deal in all kinds of drugs, medicines, Pharmaceuticals, chemicals, medical or any other preparations and to refine, manipulate or treat all such substances used in pharmaceutical industry and to do all such acts necessary in connection with any business or chemists, druggists, chemical and medicine manufacturers, pharmacists etc.

2.00 Basis of Preparation of Financial Statements:

2.01 Basis of Measurement:

The financial statements have been prepared on the Historical Cost Convention. The financial statements therefore, do not take into consideration the effect of inflation.

2.02 Statement of Compliance:

The Financial statements have been prepared in compliance with disclosures and presentational requirement of:

- Bangladesh Securities and Exchange Rules, 2020;
- The Income Tax Act, 2023 with subsequent amendments;
- The Value Added Tax Act, 2012 with subsequent amendments;
- The Value Added Tax Rules, 2012 with subsequent amendments;
- The Labour Act, 2006 with subsequent amendments in 2013;
- The Labour Law Rules, 2015; and
- Others as applicable.

2.02.01 Compliance with International Financial Reporting Standards:

IAS	Title	Remarks
IAS 1	Presentation of Financial Statements	Complied
IAS 2	Inventory	Complied
IAS 7	Statement of Cash Flows	Complied
IAS 8	Accounting Policies, Changes in Accounting Estimates and Errors	Complied
IAS 10	Events after the Reporting Period	Complied
IAS 12	Income Taxes	Complied
IAS 16	Property, Plant and Equipment	Complied
IAS 17	Leases	Complied
IAS 19	Employee Benefits	Complied
IAS 20	Accounting for Government Grants and Disclosure of Government Assistance	N/A
IAS 21	The Effects of Changes in Foreign Exchange Rates	N/A
IAS 23	Borrowing Costs	Complied
IAS 24	Related Party Disclosures	Complied
IAS 26	Accounting and Reporting by Retirement Benefit Plans	N/A
IAS 27	Separate Financial Statements	N/A
IAS 28	Investments in Associates and Joint Ventures	N/A
IAS 31	Interests in Joint Ventures	N/A
IAS 32	Financial Instruments: Presentation	Complied
IAS 33	Earnings per Share	Complied
IAS 34	Interim Financial Reporting	Complied
IAS 36	Impairment of Assets	Complied
IAS 37	Provisions, Contingent Liabilities and Contingent Assets	Complied
IAS 38	Intangible Assets	Complied
IAS 39	Financial Instruments: Recognition and Measurement	Complied
IAS 40	Investment Property	N/A
IAS 41	Agriculture	N/A
IFRS 1	First Time Adoption	N/A
IFRS 2	Share Based Payment	N/A
IFRS 3	Business Combinations	N/A
IFRS 4	Insurance Contracts	N/A
IFRS 5	Non-Current Assets Held for Sale and Discontinued Operations	N/A
IFRS 6	Exploration for and Evaluation of Mineral Resources	N/A
IFRS 7	Financial Instruments : Disclosures	Complied
IFRS 8	Operating Segments	N/A
IFRS 10	Consolidated Financial Statements	N/A
IFRS 11	Joint Arrangements	N/A
IFRS 12	Disclosure of Interests in Other Entities	Complied
IFRS 13	Fair Value Measurement	Complied
IFRS 14	Regulatory Deferral Accounts	N/A
IFRS 15	Revenue from contracts with customers	Complied
IFRS 16	Leases	Complied

2.03 Reporting Period:

The financial statements cover the period of 12 months from July 01, 2022 to June 30, 2023.

2.04 Functional and Presentation Currency:

The financial statements are prepared and presented in Bangladesh Currency (Taka), which is the Company's functional currency. Figures have been rounded off to the nearest Taka except where indicated otherwise.

2.05 Comparative Information:

Comparative information has been disclosed for all numerical information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current period's financial statements.

Comparative information has been rearranged, wherever considered necessary, to ensure better presentation and comparability with the current year.

2.06 Use of Estimates and Judgments:

The preparation of financial statements in conformity with International Financial Reporting Standards (IFRSs) including International Accounting Standards (IASs) require management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses, and for contingent assets and liabilities that require disclosure, during and at the date of the financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Any revision of accounting estimates is recognized in the period in which the estimate is revised and in any future periods affected.

In particular, the key areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements include depreciation, inventory valuation, current and deferred taxes, accrued expenses and other payables.

3.00 Significant Accounting Policies:

The Company has consistently applied the following accounting policies to all periods presented in these financial statements.

3.01 Property, Plant and Equipment:

3.1.1 Recognition and Measurement:

Items of Property, Plant and Equipment excluding land are measured at cost less accumulated depreciation in compliance with the requirements of IAS 16: "Property, Plant and Equipment".

The cost of acquisition of an asset comprises of its purchase price and directly attributable cost of bringing the asset to its working condition for its intended use inclusive of inward freight, duties and non-refundable taxes.

3.1.2 Maintenance Activities:

The Company incurs maintenance costs for all its major items of Property, Plant and Equipment. Repair and maintenance costs are charged as expenses when incurred. In the situation where it can be clearly demonstrated that the expenditure has resulted in an increase in the future economic benefit expected to be obtained from the use of the fixed assets, the expenditure is capitalized as an additional cost of the assets.

3.1.3 Depreciation:

- a) Land is held on freehold basis and is not depreciated considering the infinite life.
- b) In respect of all other PPE, depreciation is charged using Reducing Balance Method.
- c) Full month depreciation is charged on assets from when the assets are available for use, while no depreciation is charged in the month of disposal.
- d) The Company reviews the non-current assets' useful life every year and there is no change in the estimated useful life.

The depreciation rate for the current and the previous years are as follows:

Particulars	30-06-2023	30-06-2022
Factory Building	10.00%	2.50%
Plant & Machinery	20.00%	7.00%
Deep Tube Well	10.00%	15.00%
Diesel Generating Set	15.00%	15.00%
Loose Tools	10.00%	15.00%
Laboratory Equipment	10.00%	10.00%
Electrical Installation	10.00%	10.00%
Laboratory Glassware	10.00%	15.00%
Production Equipment	10.00%	10.00%
Transport and Vehicles	20.00%	20.00%
Motor Cycle	20.00%	20.00%
Furniture and Fixtures	10.00%	10.00%
Office Equipment	10.00%	15.00%
Office By-cycles	20.00%	20.00%
Books	10.00%	15.00%

3.1.4 Retirements and Disposals:

On disposal of PPE, the cost and accumulated depreciation are eliminated and gain or loss on such disposal is reflected in the Statement of Profit or Loss and Other Comprehensive Income, which is determined with reference to the net book value of the assets and net sale proceeds or realized amount.

3.1.5 Impairment:

The Company assesses at each reporting date whether there is any indication that an asset may be impaired. If any such indication exists, the Company estimates the recoverable amount of the asset and impairment loss is recognized in the statement of profit or loss and other comprehensive income. There is no impairment loss during the year under review.

3.1.6 Capital Work-in-Progress:

The non-current assets which are not ready for use at the year end, are shown as capital work-in-progress and subsequently those assets would have to be transferred to property, plant and equipment when all the necessary works are completed.

3.02 Right of Use Asset (ROU):

All leasing arrangements except those having less than 12 months of useful life and underlying asset values of less than Taka 425,000 when new, have been capitalized as "right-of-use" asset with a corresponding financial liability on the financial position.

Leased assets are capitalized from the start date of the lease agreement at the present value of the future lease payments, based on the rate of interest entered in the asset master data. Low value (<Taka 425,000) and short term leases (<12months) have been excluded from the recognition requirements and charged to statement of profit or loss as rental costs. Lease reassessment and lease modification to increase/decrease the value of an asset depending on a change in scope of lease agreement can be made if necessary.

The asset is written off on a straight-line basis over the tenure of the lease agreements. Hence, the useful life of any lease assets depends on the periods the assets can be used. The useful life of such assets are dependent on individual agreement and can vary from one agreement to another.

3.03 Borrowing Cost:

Borrowing costs are recognized as expenses in the period in which they are incurred unless capitalization of such is allowed under IAS 23: "Borrowing Costs".

3.04 Accounts Receivable and Others:

Accounts receivable are initially recognized at invoice amounts which is the fair value of the consideration given in return.

Provisions for doubtful debts are made where there is evidence of a risk of non-payment, taking into account aging, previous experience as well as general economic conditions and ultimately the prospects of realisability.

3.05 Inventories:

Inventories are carried at the lower of cost and net realizable value as prescribed by IAS 2: "Inventories". Cost is determined on a weighted average cost basis. Net realizable value of the finished goods is determined at selling price in the ordinary course of business less costs to sell, while raw and packing materials as well as accessories and components are valued at cost including expenses incurred for acquiring the inventories.

3.06 Provisions:

A provision is recognized in the financial statements when the Company has a legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provision is ordinarily measured at the best estimate of the amount to be required to settle the present obligation at the date of statement of financial position.

3.07 Employee Benefits:

The Company operates a defined contributory provident fund and Workers' Participation and Welfare Fund for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in respective deeds. The details of employee benefits are as under:

(a) Provident Fund (Defined Contribution Plan):

The Company has a recognized provident fund scheme (Defined Contribution Plan) for employees of the Company eligible to be members of the fund in accordance with the rules of the provident fund constituted under an irrevocable Trust. All permanent employees contribute a certain percentage of their basic salary to the provident fund and the Company also makes equal contribution.

The Company recognizes contribution to defined contribution plan as an expense when an employee has rendered services against such contribution. The legal and constructive obligation is limited to the amount it agrees to contribute to the fund.

(b) Contribution to Workers' Participation and Welfare Fund:

This represents 5% of net profit before tax contributed by the Company as per provisions of the Labour Act, 2006 with subsequent amendments and is transferred to Ambee Pharmaceuticals Limited Workers' Participation and Welfare Fund. The trustee of the fund manages the distribution of the WPWF according to the guidelines of the Labour Act, 2006 with subsequent amendments.

3.08 Revenue Recognition:

The Company recognizes as revenue the amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for goods or services when (or as) it transfers control to the customer. To achieve that core principle, this standard (IFRS 15) establishes a five-step model as follows:

- Identify the contract with a customer;
- Identify the performance obligations in the contract;
- Determine the transaction price;
- Allocate the transaction price to the performance obligations in the contract; and
- Recognize revenue when (or as) the entity satisfies a performance obligation.

Considering the five steps model, the Company recognizes revenue when (or as) the Company satisfies a performance obligation by transferring a promised goods to a customer. Goods are considered as transfer when (or as) the customer obtains control of that goods. Revenue from sale of goods is measured at the fair value of the consideration received or receivable net off returns and allowances, trade discounts, rebates and Value Added Tax (VAT).

3.09 Leases:

The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration.

Company as a Lessee

The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

i) Right of Use Assets (ROU)

The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any measurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised and lease payments made at or before the commencement date.

ii) Lease Liabilities

At the commencement date of the lease, the Company recognises lease liabilities measured at the present value of lease payments to be made over the lease term. In calculating the present value of lease payments, the Company uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments or a change in the assessment of an option to purchase the underlying asset.

iii) Short-Term Leases and Leases of Low-Value Assets

The Company does not apply the recognition and measurement requirements of IFRS 16 to short-term leases (leases of less than 12 months maximum duration). It also does not apply the recognition and measurement requirements of IFRS 16 to leases for which the underlying assets are low value (i.e. less than Taka 425,000 when new). Lease payments on short-term leases and leases of low-value assets are recognised as expense on a straight-line basis over the lease term.

3.10 Income Tax Expense:

(a) Current Tax

Income tax expense for current year is recognised on the basis of Company's computation based on the best estimated assessable profit for the year at the applicable tax rate pursuant to provisions of Income Tax Act, 2023. The tax rates for the period is applied based on the enacted tax rates in the relevant Finance Acts.

(b) Deferred Tax

Deferred tax is provided on temporary differences arising between the tax base of assets and liabilities and their carrying amounts in the financial statements in accordance with the provisions of IAS 12: "Income Taxes". Current ruling tax rate is used in the determination of deferred tax.

(c) Provision for Income Tax & Assessment Position:

The assessment of the company has been completed upto the assessment year 2022-2023 (Accounting year 30-06-2022). Except assessment years 2004-2005, 2005-2006, 2010-2011, 2011-2012, 2012-2013 and 2014-2015. The provision for Income tax and Advance Income Tax for these assessment years has been shown in note 18.00 and note 07.00 separately.

3.11 Earnings Per Share (EPS):

This has been calculated in compliance with the requirements of IAS 33: "Earnings per share". Earnings per share equals the basic earnings divided by the weighted average number of ordinary shares outstanding during the period.

3.12 Foreign Currency Transactions:

Foreign currency transactions are recorded at the applicable rates of exchange ruling at the transaction date.

The monetary assets and liabilities, denominated in foreign currencies at the financial position date are translated at the applicable rates of exchange ruling at that date. Exchange differences are treated as revenue/expense in compliance with the provisions of IAS 21: "The Effects of Changes in Foreign Exchange Rates".

3.13 Statement of Cash Flows:

The statement of cash flows has been prepared in accordance with the requirements of IAS 7: "Statement of Cash Flows". The cash generated from operating activities has been reported using the direct method as prescribed by the Securities and Exchange Rules, 2020 and following the benchmark treatment of IAS 7, whereby major classes of gross cash receipts and gross cash payments from operating activities are disclosed.

In accordance with the gazette notification dated 08 August 2018 from Bangladesh Securities and Exchange Commission, an additional disclosure on reconciliation of net cash flows from operating activities making adjustments for non-cash items, non-operating and net changes in operating accruals has been provided in note 29.00.

4.00 Right of Use Asset (ROU), Net:

This is made-up as follows:

Particulars	Note	30-06-2023	30-06-2022
Opening Balance		686,528	1,954,507
Add: Addition during the year		-	-
		686,528	1,954,507
Less: Depreciation charged during the year	23.00	549,186	1,267,979
Closing Balance		137,342	686,528

5.00 Inventories:

This is made-up as follows:

Particulars	30-06-2023	30-06-2022
Raw materials	24,058,754	21,424,953
Packing materials	28,763,547	38,190,426
Promotional materials	445,874	781,321
Work-in-process	15,875,426	14,974,343
Finished goods	117,661,579	103,365,308
Materials-in-transit	10,442,745	151,696
Closing Balance	197,247,925	178,888,046

6.00 Accounts Receivables:

6.01 The details given as follows:

Particulars	Note	30-06-2023	30-06-2022
Opening Balance		112,510,672	92,227,940
Add: Addition during the year	21.00	198,095,938	180,993,450
		310,606,610	273,221,390
Less: Received during the year		174,662,655	160,710,718
Closing Balance		135,943,955	112,510,672

6.02 This is made-up as follows:

Particulars	30-06-2023	30-06-2022
Above Six months	67,425,475	55,773,872
Below Six months	68,518,480	56,736,800
Total:	135,943,955	112,510,672

6.03 Accounts receivable is considered good in terms of security and previous collection history. Party wise balance of receivable was not available.

7.00 Advance Income Tax:

This is made-up as follows-

Particulars	30-06-2023	30-06-2022
Opening Balance	49,296,762	48,643,968
Add: Addition during the year	2,635,798	1,702,439
	51,932,560	50,346,407
Less: Adjustment during the year	32,354,267	1,049,645
Closing Balance	19,578,293	49,296,762

7.01 Year Wise Break-up Details:

Assessment years	Accounting Year	30-06-2023	30-06-2022
Opening Balance		-	32,354,267
2004-2005	30-06-2004	941,043	941,043
2005-2006	30-06-2005	2,690,695	2,690,695
2010-2011	30-06-2010	2,783,817	2,783,817
2011-2012	30-06-2011	3,688,461	3,688,461
2012-2013	30-06-2012	1,435,640	1,435,640
2014-2015	30-06-2014	5,402,839	5,402,839
2023-2024	30-06-2023	2,635,798	-
Total:		19,578,293	49,296,762

8.00 Advances, Deposits and Prepayments:

This is made-up as follows:

Particulars	30-06-2023	30-06-2022
Advances	43,893,703	42,108,130
Advances to Staff	2,354,875	2,050,874
Advance Rent	118,000	118,000
Against Purchases and Expenses	20,548,752	19,067,180
Bengal Steel Works Limited	20,774,090	20,774,090
Ambee Films Limited	97,986	97,986
Deposits	1,181,020	9,353,330
L/C Margin	1,160,305	8,041,150
Guarantee Margin	20,715	20,715
Other Deposits	-	1,291,465
Prepayments	25,000	25,000
WASA	25,000	25,000
Total:	45,099,723	51,486,460

9.00 Cash and Cash Equivalents:

This is made-up as follows:

Particulars	Notes	30-06-2023	30-06-2022
Cash in Hand	9.01	27,479,794	16,112,264
Cash at Bank	9.02	1,030,724	729,557
In-Operative Accounts	9.03	57,415	81,515
Total:		28,567,933	16,923,336

9.01 Cash in Hand:

This is made-up as follows:

Particulars	30-06-2023	30-06-2022
Head Office	112,825	10,345
Factory	507	10,601
DASC	111,290	16,222
DBSC	1,675,423	354,875
MNSC	2,880,650	1,772,635
BGSC	2,803,535	1,772,328
RJSC	2,784,585	1,768,406
RNSC	2,991,300	1,724,261
BLSC	2,905,240	1,721,633
KLSC	2,821,295	1,691,349
CMSC	2,778,784	1,818,070
CGSC	2,684,450	1,620,887
SLSC	2,929,910	1,830,652
Total:	27,479,794	16,112,264

The above balance have been confirmed by certificate.

9.02 Cash at Bank:

This is made up as follows:

Name of Bank	30-06-2023	30-06-2022
Easteran Bank Ltd., Gulshan Branch Dhaka, A/C # 104-107-0000-139	30,222	30,912
Easteran Bank Ltd., Gulshan Branch Dhaka, A/C # 104-107-0004854	4,439	5,129
Sonali Bank Ltd., Gulshan Branch Dhaka, A/C # 33004754	213,043	213,504
Sonali Bank Ltd., Gulshan New North Circle Branch, A/C # 011633002105	13,978	31,248
Agrani Bank Ltd, Amin Court Branch, CD A/C # 0004263	57,570	58,260
Agrani Bank Ltd, Amin Court Branch, Dividend A/C # 0001724	370,819	153,954
Unitied Commercial Bank Ltd., CD A/C # 0951101000002665 (Dormant)	235,459	236,299
Unitied Commercial Bank Ltd., Tejgaon Branch, CD A/C # 1041101000000972	30,164	251
Dutch-Bangla Bank Ltd.,A/c. No. 2271100018251	2,328	-
Dutch-Bangla Bank Ltd.,A/c. No. 2271100018272	2,583	-
Dutch-Bangla Bank Ltd.,A/c. No. 2271100018267	7,553	-
Padma Bank Ltd.,A/c. No. 0060111000147	62,566	-
Total:	1,030,724	729,557

The above balances have been confirmed with the respective bank statements.

9.03 In-Operative Accounts:

This is made up as follows:

Name of Bank	30-06-2023	30-06-2022
Agrani Bank Ltd. Press Br. Club Acc-892-4	321	321
Agrani Bank Ltd. Chatteswari Road Br. Acc-1840	397	397
Agrani Bank Ltd. Cumilla Br. CA Acc-52982	99	99
Shamil Bank of bahrain E.C Acc-301-2015633-001 (Written-off)	-	24,100
Habib Bank Ltd. Dhaka. Acc-5133-72	6	6
Sonali Bank Custom House Br. CD-A-3	25,327	25,327
Arab Bangladesh bank Ltd. Acc-1962	29,349	29,349
First Security Bank Ltd. Dhaka. Acc-1100724-9	100	100
Agrani Bank, Battala Br. Barisal. Acc-33002491	816	816
Agrani Bank Ltd. Central road br. Rangpur. C/A Acc-4752	1,000	1,000
Total:	57,415	81,515

10.00 Share Capital:

10.01 This is made up as follows:

Particulars	30-06-2023	30-06-2022
a) Authorized		
30,000,000 Ordinary Shares of Taka 10 each	<u>300,000,000</u>	<u>25,000,000</u>
b) By Cash Issued Subscribed and Paid-Up Capital		
i) 1,821,008 Ordinary Shares of Tk. 10 each fully Paid Up in cash.	18,210,080	18,210,080
ii) Other than Cash		
178,992 Ordinary Shares of Tk. 10 each paid-up in full for consideration other than cash	1,789,920	1,789,920
c) By issue of Bonus Share		
400,000 Bonus Shares of Tk.10 each Issued for the year 2013	4,000,000	4,000,000
Total:	<u>24,000,000</u>	<u>24,000,000</u>

10.02 Composition of Shareholdings

Particulars	30-06-2023		30-06-2022	
	No of Shares	%	No of Shares	%
Sponsors, Directors & Associates	1,639,269	68.30	1,639,269	68.30
ICB & Institutions	130,372	5.43	219,842	9.16
Foreign Investors	214,790	8.95	214,790	8.95
General Public	415,569	17.32	326,099	13.59
Total:	<u>2,400,000</u>	<u>100</u>	<u>2,400,000</u>	<u>100.00</u>

10.03 The distribution schedule of the shares is given below:

Range of Holdings	Number of Shareholders	No. of Shares	Holdings (%)
01 to 500 shares	1973	153,710	6.40
501 to 5,000 shares	131	180,647	7.53
5,001 to 10,000 shares	7	49,021	2.04
10,001 to 20,000 shares	7	104,685	4.36
20,001 to 30,000 shares	-	-	-
30,001 to 40,000 shares	-	-	-
40,001 to 50,000 shares	4	192,120	8.01
50,001 to 100,000 shares	1	57,878	2.41
100,001 to 1,000,000 shares	1	214,790	8.95
Over 1,000,000 shares	1	1,447,149	60.30
Total:	<u>2,124</u>	<u>2,400,000</u>	<u>100.00</u>

10.04 The share are listed in the Dhaka and Chittagong Stock Exchange On 30.06.2023 each share was quoted at Tk 551.4 in the Dhaka Stock Exchange Ltd. and Tk 532.9 in the Chittagong Stock Exchange Ltd.

11.00 Tax-Holiday Reserve:

5,134,154 5,134,154

This was created out of profit during Tax-Holiday period to invest in the same undertaking or in any new industrial undertaking or in stocks and shares of a public company or in government bonds or securities or for other purposes as specified in this respect as one of the condition of granting Tax Holiday. But no such investment has been made.

12.00 Deferred Tax Liability:

This is made up as follows:

Particulars	Notes	30-06-2023	30-06-2022
Carrying value of depreciable PPE-As per Accounts	Schedule-A	37,225,995	44,106,073
Tax Base Value	Schedule-B	(12,743,239)	(15,357,666)
		24,482,756	28,748,407
Temporary difference for IFRS 16: Lease	12.01	10,943	(79,887)
Tax Base Value		-	-
		10,943	(79,887)
Net taxable temporary difference- Liabilities		24,493,699	28,668,520
Tax Rate		25.00%	25.00%
Deferred Tax Liability - Closing		6,123,425	7,167,130
Deferred Tax Liability- Opening		7,167,130	7,038,819
Deferred Tax (Expenses)/Income for the year		1,043,705	(128,311)

12.01 The temporary difference figure has been computed by deducting ROU Assets from Lease liabilities and multiply by 25% tax rate thereon in order to calculate deferred tax (assets)/liability value. The details are as follows:

13.00 Lease Finance:

13.01 This is made up as follows:

Particulars	30-06-2023	30-06-2022
Loan From Lease Fianance	315,491	1,582,426
Less: Current Portion of long term loan being payable within one year	(315,491)	(315,491)
	-	1,266,935
Obligation Under Finance Leases		
Gross Finance Lease- minimum lease liability		
Within one year	-	315,491
After one year	-	-
Total:	-	315,491
Less: Future finance charges on finance lease liability	-	-
Present Value of Finance Lease liability	-	315,491
This consist of as follows:		
Within one year	-	315,491
Within two to five years	-	-
Total Present Value of Finance Lease liability	-	315,491

13.02 Leases:

This is made-up as follows:

Particulars	30-06-2023	30-06-2022
Opening Balance as at 1st July, 2022	766,415	2,022,890
Add: Interest Accrued	116,507	209,253
	882,922	2,232,143
Less: Payments	756,523	1,465,728
Closing Balance as at 30 June, 2023	126,399	766,415

Lease Liabilities Recognized in Statement of Financial Position

Lease Liability - Net off Current Maturity	-	9,896
Lease Liability - Current Maturity	126,399	756,519
Total:	126,399	766,415

14.00 Short Term Borrowings:

This is made up as follows:

Particulars	30-06-2023	30-06-2022
United Commercial Bank Ltd, Tejgaon Branch, A/C- No. 104174900000115 (Overdraft Facilities)	-	55,947,683
United Commercial Bank Ltd, Tejgaon Branch, A/C- No. 104174900000115 (Letter of Trust Receipt)	11,480,430	8,074,080
Total:	11,480,430	64,021,763

The above balance have been confirmed with the respective bank statement.

15.00 Creditors for Goods & Others:

This represents amounts due to various suppliers of raw, packing and stores materials, the ageing of which liability is as follows:

Particulars	30-06-2023	30-06-2022
Above six months	-	-
Below six months	4,981,983	6,549,924
Total:	4,981,983	6,549,924

16.00 Liabilities for Expenses:

This represents provision for various expenses (e.g. remuneration and allowances, salaries and wages, utilities bills etc.), which have fallen due as on 30th June, 2023, ageing of which liability is as follows

Particulars	30-06-2023	30-06-2022
Above six months	-	-
Below six months	6,025,487	7,201,295
Total:	6,025,487	7,201,295

16.01 Details of above balance are given below:

Salary, wages & Allowance	4,524,879	5,354,871
Electricity, Gas & Water	505,454	875,423
Audit Fees	402,500	402,500
Telephone & Internet Bill	63,900	83,254
TA/DA & Other	528,754	485,247
Total:	6,025,487	7,201,295

17.00 Liabilities for other Finance:

This is made up as follows:

Particulars	30-06-2023	30-06-2022
Opening Balance	316,269,940	183,594,643
Add: Addition during the year	106,092,250	159,670,835
Loan from Ambee Limited	35,048,250	149,684,335
Loan from Kazi Tanzzina Ferdous	1,044,000	10,000,000
Loan from Aziz Mohammad Bhai	70,000,000	-
Less: Adjustment during the year	5,000,000	26,995,538
VAT Paid	-	26,995,538
Loan Refund to Ambee Limited	5,000,000	-
Closing balance	417,362,190	316,269,940

17.01 Details of above balance are given below:

Particulars	Notes	30-06-2023	30-06-2022
Employees Income Tax		701,137	701,137
Vat Payable	17.02	13,441,194	13,441,194
Income Tax Deduction from Supplier		431,369	431,369
Provident Fund Payable		1,916,358	1,916,358
Loan from Mr. Aziz Mohammad Bhai	17.03	190,093,891	120,093,891
Loan from Kazi Tanzzina Ferdous		11,044,000	10,000,000
Loan from Ambee Limited		179,732,585	149,684,335
Balance of provision for Interest	17.03	20,001,655	20,001,655
Total:		417,362,190	316,269,940

17.02 Vat Payable:

This is made up as follows:

Particulars	30-06-2023	30-06-2022
Opening Balance	13,441,194	40,436,732
Add: Provision for the year	-	-
	13,441,194	40,436,732
Less: Adjustment during the year	-	26,995,538
Closing Balance	13,441,194	13,441,194

17.03 Out of total balance of Tk 417,362,190 an amount of Tk 190,093,891 is payable to Aziz Mohammad Bhai, Chairman of the Company as disclosed at Note # 30 "Related party transactions". Interest payable amounting to Taka 20,001,655 is coming from previous years.

18.00 Provision for Income Tax:

This is made up as follows:

Particulars	Note	30-06-2023	30-06-2022
Opening Balance		36,343,933	38,442,953
Add: Provision for the year	18.01	2,635,798	2,046,890
		38,979,731	40,489,843
Less: Adjustment during the year		(7,439,519)	(4,145,911)
Closing Balance		31,540,212	36,343,933

18.01 Income Tax Expenses:

The calculation of profit for income tax for the year is as follows:

Particulars	30-06-2023	30-06-2022
a) On net profit 22.5%	2,403,504	2,046,890
b) On gross receipt, Section-163(6) @ 0.6%	1,188,576	1,085,961
c) Advance Income Tax (deduction & advanced payment)	2,635,798	1,702,439
Whichever is Higher (a,b,c)	2,635,798	2,046,890

18.01.01 Year Wise payable Details:

Assessment years	Accounting Year	30-06-2023	30-06-2022
Opening Balance		-	7,439,519
2004-2005	30-06-2004	9,151,172	9,151,172
2005-2006	30-06-2005	8,722,496	8,722,496
2010-2011	30-06-2010	2,302,815	2,302,815
2011-2012	30-06-2011	2,637,588	2,637,588
2012-2013	30-06-2012	2,228,549	2,228,549
2014-2015	30-06-2014	3,861,794	3,861,794
2023-2024	30-06-2023	2,635,798	-
	Total:	31,540,212	36,343,933

19.00 Workers Participation and Welfare Fund (WPWF):

This is made up as follows:

Particulars	Note	30-06-2023	30-06-2022
Opening Balance		10,459,676	9,948,826
Add: Provision for the year		562,223	511,723
Add: Interest during the year @ 11.5%	25.00	1,202,863	1,144,115
		12,224,762	11,604,664
Less: Adjustment/ payment during the year		511,723	1,144,988
Closing Balance		11,713,039	10,459,676

20.00 Unclaimed Dividend:

The following figures represent the dividends for which the warrants are either lying with the shareholders and have not been presented as yet by them to the bank for encashment or have been returned to the company undelivered due to change of address of those shareholders and their new address have not yet been communicated to the company. Under instruction from SEC, press advertisements were made to collect the past dividend warrants but many shareholders are yet turn up to collect their respective warrants.

Particulars	30-06-2023	30-06-2022
Opening Balance	2,356,352	3,856,352
Add: Dividend during the year	2,400,000	-
	4,756,352	3,856,352
Less: Dividend paid during the year	2,120,000	-
Dividend Tax paid during the year	280,000	-
Less: Transfer to Capital Market Stabilization Fund (CMSF)	1,000,000	1,500,000
Total:	1,356,352	2,356,352

20.01 During the year 2023 amount of Tk. 1,000,000 has been transferred in favour of the Capital Market Stabilization Fund (CMSF) following the BSEC directive number DSE/Listing/327/2021/6245-107 dated 16 Sept. 2021.

21.00 Revenue:

This is made up as follows:

Particulars	30-06-2023	30-06-2022
Local Sales	224,793,879	208,142,467
Less: VAT	29,320,941	27,149,017
	195,472,938	180,993,450
Add: Export Sales	2,623,000	-
Total:	198,095,938	180,993,450

21.01 Sales Quantity:

This is made up as follows:

Particulars	UOM	Qty.	30-06-2023	30-06-2022
Tablet	Pcs.	39,752,442	156,814,435	136,840,635
Capsules	Pcs.	15,970,440	33,314,389	30,340,425
Liquids	Bottles	62,999	1,209,415	2,688,922
Ointment	Pcs.	413	4,023	35,827
Injection	Ampoule	2,018,890	6,753,676	11,087,641
Total:		57,805,184	198,095,938	180,993,450

22.00 Cost of Goods Sold:

This is made up as follows:

Particulars	Notes	30-06-2023	30-06-2022
Work-in-process (Opening)		14,974,343	2,245,635
Raw materials consumed	23.01	35,137,077	60,442,784
Packing materials consumed	23.02	44,373,608	43,145,404
Promotional materials consumed	23.03	1,390,319	4,558,807
Factory overhead	23.04	25,946,843	18,256,102
Depreciation	Schedule-A	4,537,064	1,661,012
Work-in-process (Closing)		(15,875,426)	(14,974,343)
Cost of production		110,483,828	115,335,401
Stock of finished goods (Opening)		103,365,308	77,797,903
Stock of finished goods (Closing)		(117,661,579)	(103,365,308)
Cost of free samples		(1,220,365)	(1,025,874)
Total:		94,967,192	88,742,122

22.01 Raw Materials Consumption:

This is made up as follows:

Particulars	Active Ingredients (KG)	Excipients (KG)	E.H.G. Capsules (PCS)	30-06-2023	30-06-2022
Opening Stock	426	5,800	872,300	21,424,953	19,976,650
Purchase	7,560	887	2,356,951	37,770,878	61,891,087
Closing Stock	879	6,215	2,979,251	(24,058,754)	(21,424,953)
Total:	7,107	472	250,000	35,137,077	60,442,784

Raw materials consumption is 97.33% imported.

22.02 Packing Materials Consumed:

This is made up as follows:

Particulars	30-06-2023	30-06-2022
Opening Stock	38,190,426	27,987,893
Purchase	34,946,729	53,347,937
Closing Stock	(28,763,547)	(38,190,426)
Total:	44,373,608	43,145,404

Packing materials consumed is nil % imported.

Particulars in respect of quantity of each packing materials as well as value of each class of packing materials are not given as number of items as well as classes of items are large.

22.03 Promotional Materials Consumed:

This is made up as follows:

Particulars	30-06-2023	30-06-2022
Opening Stock	781,321	880,630
Purchase	1,054,872	4,459,498
Closing Stock	(445,874)	(781,321)
Total:	1,390,319	4,558,807

Particulars in respect of quantity of each promotional materials as well as value of each class of promotional materials are not given as number of items as well as classes of items are large.

22.04 Factory Overhead:

This is made up as follows:

Particulars	30-06-2023	30-06-2022
Salary, wages and allowances	20,897,428	12,381,124
Overtime allowances	231,151	452,835
Car Expenses	336,393	453,231
Electricity, Gas and Water	3,222,180	3,149,205
Conveyance	84,055	69,706
Entertainment	69,159	85,649
Printing and Stationery	162,932	190,929
Repairs and maintenance	385,364	818,595
Telephone	126,116	180,900
Indirect materials-Packing	233,100	342,956
Uniform	21,587	14,557
General Expenses	43,781	43,188
Washing & Laundry Expenses	20,081	16,083
Power & Fuel	113,516	57,144
Total:	25,946,843	18,256,102

23.00 Administrative Expenses

This is made up as follows:

Particulars	Notes	30-06-2023	30-06-2022
Salary and Allowances		15,448,789	12,287,456
Car Expenses		214,271	160,574
Bank Charges		140,325	108,714
Conveyance		262,461	192,343
Entertainment		270,978	509,049
Printing and Stationery		160,465	164,449
Electricity, Gas and Water		805,544	774,434
Repairs and Maintenance		66,874	139,715
Telephone		397,130	286,532
Fees and Commissions		150,365	480,410
Membership Subscription		163,132	183,132
Audit Fees (Statutory)		402,500	402,500
Insurance Premium		48,752	37,492
Legal and Professional Charges		20,354	60,800
AGM Expenses		99,020	125,390
Shamil Bank of bahrain E.C Acc-301-2015633-001 (Written-off)		24,100	-
Other Deposit (Written-off)		1,291,465	-
Advertisement & Publicity		40,344	18,489
Depreciation	Schedule-A	2,449,764	3,124,194
Depreciation on Right of Use Asset	4.00	549,186	1,267,979
Total:		23,005,820	20,323,652

24.00 Selling, Distribution and Marketing Expenses:

This is made up as follows:

Particulars	30-06-2023	30-06-2022
Salary and Allowances	49,515,308	35,667,437
Rent, Rates and Taxes	875,325	1,650,870
Car Expenses	114,271	354,785
Bank charges	287,654	274,254
Commercial Booking Cost	875,462	2,026,373
Conveyance	240,658	222,512
Entertainment	87,563	176,915
Postage expenses	32,327	25,472
Printing and Stationery	41,133	304,168
Repairs and maintenance	110,254	326,290
Telephone	737,624	624,525
Electricity, Gas and Water	240,587	238,929
Commission Charge	146,003	198,932
TA/DA of MR and others	5,471,040	5,774,772
General expenses	28,547	38,360
Meeting/Conference/Training expenses	280,325	390,524
Delivery Van expenses	140,587	214,862
Delivery expenses	5,085,935	5,484,680
Free Sample	875,462	1,420,554
Total:	65,186,065	55,415,214

25.00 Financial Expenses:

This is made up as follows:

Particulars	Note	30-06-2023	30-06-2022
Interest on Overdraft		2,486,141	4,478,770
Interest on Lease Finance		3,395	143,404
Interest on WPWF	19.00	1,202,863	1,144,115
Total:		<u>3,692,399</u>	<u>5,766,289</u>

26.00 Basic Earnings Per Share:

This is made up as follows:

Particulars	30-06-2023	30-06-2022
Earning attributable to the Ordinary Shareholders (Net Profit/Loss after tax)	9,090,147	8,059,249
Weighted average number of Ordinary shares outstanding during the year	2,400,000	2,400,000
	<u>3.79</u>	<u>3.36</u>

27.00 Net Asset Value:

This is made up as follows:

Particulars	30-06-2023	30-06-2022
Non-Current Assets	87,612,878	95,042,142
Current Assets	426,437,829	409,105,276
Non-Current Liabilities	6,123,425	7,177,026
Current Liabilities	484,586,094	444,274,894
Total:	<u>23,341,188</u>	<u>52,695,498</u>
Number of Ordinary Shares	2,400,000	2,400,000
NAV - Per Share	<u>9.73</u>	<u>21.96</u>

28.00 Net Operating Cash Flow per Share:

This is made up as follows :

Particulars	30-06-2023	30-06-2022
Cash flows from net operating activities as per statement of cash flows	(35,232,341)	(73,180,286)
Weighted average number of ordinary shares outstanding during the year	2,400,000	2,400,000
Net Operating Cash Flow Per Share	<u>(14.68)</u>	<u>(30.49)</u>

29.00 Reconciliation of Net Cash flows from Operating Activities:

This is made up as follows :

Particulars	30-06-2023	30-06-2022
Cash flow from Operating Activities:		
As per direct method	<u>(35,232,341)</u>	<u>(73,180,286)</u>
Net Profit after Tax	9,090,147	8,059,249
Adjustments	6,492,309	6,181,494
Depreciation on Property, Plant & Equipment	6,986,828	4,785,204
Depreciation on Right of Use Asset	549,186	1,267,979
Deferred Tax	(1,043,705)	128,311
Changes in Working Capital	(50,814,797)	(87,421,030)
Increase in Inventories	(18,359,879)	(49,999,335)
Increase in Accounts Receivable & Others	(23,433,283)	(20,282,732)
Increase in Advances, Deposits & Prepayments	6,386,737	(14,486,279)
Increase in Advances Income Tax	29,718,469	(652,794)
Decrease in Creditor for Goods	(1,567,941)	(665,096)
Decrease in Liabilities for Expenses	(1,175,808)	467,733
Increase in Provision for Income Tax	(7,591,998)	(2,099,020)
Increase in Worker Profit Participation Fund	1,253,363	510,850
Prior year adjustment provision by Tax Assessment	(36,044,456)	(214,358)
Net Cash Generated from Operating Activities	<u>(35,232,341)</u>	<u>(73,180,286)</u>

30.00 Related Party Transactions - Disclosure Under IAS 24:

The Company has entered into transactions with other entities that fall within the definition of related party as contained in IAS-24 "Related Party Disclosures". The Company opines that terms of related party transactions do not significantly differ from those that could have been obtained from third parties. Total transactions of the significant related parties as at 30 June 2023 were as follows:

Name of the Party	Relationship	Nature of Transaction	Notes	Opening Balance	Addition during the year	Adjustment during the year	Closing Balance
Bengal Steel Works Limited	Group Concern	Inter company Loan/ Receivable	8.00	20,774,090	-	-	20,774,090
Ambee Films Limited	Group Concern	Inter company Loan/ Receivable	8.00	97,986	-	-	97,986
Kazi Tanzzina Ferdous	Managing Director	Inter company Loan/ Receivable	17.02	10,000,000	1,044,000	-	11,044,000
Ambee Limited	Group Concern	Inter company Loan/ Receivable	17.02	149,684,335	35,048,250	5,000,000	179,732,585
Aziz Mohammad Bhai	Chairman	Inter company Loan/ Receivable	17.04	120,093,891	70,000,000	-	190,093,891
Total:				300,650,302	106,092,250	5,000,000	401,742,552

Note: Out of total amount of Tk. 179,732,585 of Ambee Limited from the above table, The amount of Tk. 35,048,250 is included from the running year 2022. Company will take permission from the share holders in the next Annual General Meeting.

31.00 Salaries / Perquisites to Directors & Officers:

During the year, the amount of compensation paid to Key Management Personnel including Board of Directors is as under (As Para 17 of IAS 24 Related Party Disclosures):

Short Term Employee Benefits	-	-
Post- Employment Benefits	-	-
Other Long-Term Benefits	-	-
Termination Benefits	-	-
Others	-	-
Total:	-	-

There is no other benefits provided by the company to it's employees other than a contributory Provident Fund Scheme.

31.01 Directors Remuneration:

During the year total remuneration paid to directors amounting to Tk. Nil

31.02 Number of Employees:

Total number of employees of the Company was 477 as on 30 June, 2023.

Total number of employees of the Company was 425 as on 30 June, 2022.

32.00 Financial Risk Management:

(a) Credit risk

Credit risk is the risk of a financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's receivables. Management has a credit policy in place and exposure to credit risk is monitored on an ongoing basis. Risk exposures from other financial assets, i.e. cash at bank and other external receivables are nominal.

Exposure to credit risk

Particulars	Notes	30-06-2023	30-06-2022
Accounts Receivable & Others	6.00	135,943,955	112,510,672
Cash & Cash Equivalents	9.00	28,567,933	16,923,336
Total:		164,511,888	129,434,008

The aging of trade receivables at the reporting date was:

Particulars	30-06-2023	30-06-2022
Dues below 6 months	68,518,480	56,736,800
Dues over 6 months	67,425,475	55,773,872
Total:	135,943,955	112,510,672

b) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations when they fall due. The Company's approach to managing liquidity (cash and cash equivalents) is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation. Typically, the Company ensures that it has sufficient cash and cash equivalents to meet expected operational expenses, including financial obligations through preparation of the cash flow forecast, prepared based on time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/fund to make the expected payment within due date. In extreme stressed conditions, the Company may get support from the related Company in the form of short term financing.

(c) Market risk

Market risk is the risk that any change in market prices such as foreign exchange rates and interest will affect the Company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters.

(i) Currency risk

The Company is exposed to currency risk on certain purchases such as import of raw & packing materials, machineries and equipment. Majority of the Company's foreign currency transactions are denominated in USD and relate to procurement of raw & packing materials, machineries and equipment from abroad.

(ii) Interest rate risk

Interest rate risk is the risk that arises due to changes in interest rates on borrowing. There was no foreign currency loan which is subject to floating rates of interest. Local loans are, however, not significantly affected by fluctuations in interest rates. The Company has not entered into any type of derivative instrument in order to hedge interest rate risk as at the reporting date.

33.00 Production Capacity & Capacity Utilization:

Products	On single shift basis		Remarks
	Production capacity	Actual production	
Tablet group (Pcs)	1,200,000	1,100,000	As per market demand
Capsule group (Pcs)	384,000	288,000	As per market demand
Suspension group (Bottles)	8,000	7,000	-do-
Injectable (Ampoules)	35,000	30,000	-do-
Tube	7,500	5,000	-do-

34.00 Capital Expenditure Commitment:

The Board of Directors of the company adopted the following decisions with regard to Capital Expenditures:

There was no material capital expenditure authorized by the Board but not contracted for at June 30, 2023.

35.00 Contingent Liabilities:

There may arise contingent liability for unassessed income tax cases pending with Tax Department.

36.00 Payments made in Foreign Currency:

This is made up as follows:

Particulars	30-06-2023	30-06-2022
Import of Raw material	36,762,372	8,509,188
Import of Packing material	-	7,276,573
Total:	<u>36,762,372</u>	<u>15,785,761</u>

No other expenses including royalty, technical expert and professional advisory fees, interest etc. was incurred or paid in foreign currencies except as stated above.

37.00 Going Concern:

The financial statements of the Company are prepared on a going concern basis. As per management assessment there are no material uncertainties related to events or conditions which may cast significant doubt upon Company's ability to continue as a going concern. The management do not see any issue with respect to going concern due to recent pandemic COVID-19. Besides, the management is not aware of any other material uncertainties that may cast significant doubt upon the Company's ability to continue as a going concern, which is most unlikely though yet considering overall perspectives.

38.00 Events after the Reporting Period:

Subsequent to the date of financial statement, the Board of Directors in its meeting held on2023 has not proposed any dividend which will be approved by the shareholders in the annual general meeting.


Excepting to that, no circumstances have arisen since the date of statement of financial position which would require adjustment to, or disclosure in, the financial statements or notes thereto.

39.00 Approval of the Financial Statements:

These financial statements were authorized for issue in accordance with the resolution of the Company's Board of Directors in its meeting held on2023.



Naureen Aziz Mohammad Bhai
Vice Chairperson and Chief Executive
Officer (CEO)



Kazi Tanzina Ferdous
Director



Nurjahan Huda
Director



A.K.M Khairul Aziz
Chief Financial Officer



Mohammad Amir Hossain
Company Secretary

Dated: Dhaka, November 06, 2023

AMBEE PHARMACEUTICALS PLC
Property, Plant & Equipment
Depreciation Schedule as per Income Tax
For the year ended June 30, 2023

Schedule-B

Particulars	WDV As on 01.07.2022	Addition during year	Adjustment during year	As on 30.06.2023	Rate %	Depreciation	WDV As on 30.06.2023
Existing Units -1							
Land	-	-	-	-	-	-	-
Leasehold Land	-	-	-	-	-	-	-
Factory Building	192,932	-	-	192,932	10	19,293	173,639
Plant and Machinery	1,318,784	-	-	1,318,784	20	263,757	1,055,027
Loose Tools	406	-	-	406	10	41	365
Laboratory Equipment	802,762	-	-	802,762	10	80,276	722,486
Electrical Installation	56,340	-	-	56,340	10	5,634	50,706
Laboratory Glass Ware	317	-	-	317	10	32	285
Production Equipment	44,997	-	-	44,997	10	4,500	40,497
Transport and Vehicles	1,466,623	-	-	1,466,623	20	293,325	1,173,298
Motorcycle	8,903,094	-	-	8,903,094	20	1,780,619	7,122,475
Furniture and Fixtures	567,769	-	-	567,769	10	56,777	510,992
Office Equipment	1,783,876	106,750	-	1,890,626	10	185,201	1,705,425
Office By-cycles	44	-	-	44	20	9	35
Books	1,250	-	-	1,250	10	125	1,125
	-	-	-	-	-	-	-
Sub Total	15,139,194	106,750	-	15,245,944	-	2,689,587	12,556,357
Injectable (Ampoule) Unit -2							
Factory Building	28,351	-	-	28,351	10	2,835	25,516
Plant and Machinery	87,379	-	-	87,379	20	17,476	69,903
Production Equipment	1,122	-	-	1,122	10	112	1,010
Transport and Vehicles	10,054	-	-	10,054	20	2,011	8,043
Furniture and Fixture	91,566	-	-	91,566	10	9,157	82,409
Sub Total	218,472	-	-	218,472	-	31,591	186,882
Grand Total	15,357,666	106,750	-	15,464,416	-	2,721,177	12,743,239